Search Login Register

Cholangiocarcinoma Summary

Description: A malignant tumor arising from the intrahepatic bile duct epithelium. It is composed of ducts lined by cuboidal or columnar cells that do not contain bile, with abundant stroma. (From Holland et al., Cancer Medicine, 3d ed, p1455; Stedman, 25th ed)

Also Known As: Cholangiocarcinomas; Cholangiocellular Carcinoma

Networked: 3115 relevant articles (130 outcomes, 411 trials/studies) for this Disease

Key Drugs and Agents for Cholangiocarcinoma

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. 1-phenyl-3,3-dimethyltriazene (PDT) : 12 outcomes 15 studies in 51 results : IBA
  2. gemcitabine : 9 outcomes 31 studies in 87 results : FDA 7
  3. Primary sclerosing cholangitis : 5 outcomes 12 studies in 275 results : IBA
  4. Bismuth : 4 outcomes 7 studies in 70 results : IBA
  5. Plastics : 4 outcomes 1 study in 11 results : IBA
  6. Cisplatin (Platino) : 3 outcomes 12 studies in 39 results : FDA 6 Generic
  7. oxaliplatin (Eloxatin) : 3 outcomes 3 studies in 14 results : FDA 14 Generic
  8. Proteins (Proteins, Gene) : 2 outcomes 10 studies in 52 results : IBA
  9. celecoxib (Celebrex) : 2 outcomes 2 studies in 8 results : FDA 2
  10. lapatinib (GW572016) : 2 outcomes 1 study in 3 results : FDA 1
Show All >>

Diseases Related to Cholangiocarcinoma

  1. Neoplasms (Cancer)
  2. Carcinoma (Carcinomatosis)
  3. Neoplasm Metastasis (Metastasis)
  4. Cholestasis
  5. Biliary Tract Neoplasms (Biliary Tract Cancer)
Show All >>

Key Therapies for Cholangiocarcinoma

Efficacy Chart >>
  1. Photochemotherapy (Photodynamic Therapy) : 19 outcomes 19 studies in 93 results
  2. Liver Transplantation : 14 outcomes 8 studies in 217 results
  3. Stents : 13 outcomes 17 studies in 103 results
  4. Drug Therapy (Chemotherapy) : 10 outcomes 23 studies in 170 results
  5. Radiotherapy : 10 outcomes 13 studies in 87 results
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.